It has been suggested in studies that when Sema4D antibodies are combined with immune checkpoint inhibitors, such as the anti-Sema4D antibody Pepinemab, and combined with the immune checkpoint inhibitor PD-L1 mAb Avelumab, they can enhance T-cell activity, thus persistently inhibiting tumor growth (40). Here, SEMA4D is linked to neoplasm.